Navigation Links
24x7 Infection Control, Inc. Announces World's First, Modern “Shield” Against Microbial Contamination
Date:3/5/2010

Microbial contamination is the third leading cause of mortality in the U.S., according to the Centers for Disease Control (CDC).

Charleston, SC (PRWEB) March 5, 2010 -- Today’s hospitals have an increasingly dangerous and costly problem. The culprit…Hospital Acquired Infections (HAIs) and they have generated much attention over the last decade. Studies have shown that up to 70% of HAIs are preventable with proper infection control, according to a Nurse Liaison for 24x7 Infection Control, Inc.    

A totally new (to the public) antimicrobial line named Goldshield®™ is a revolutionary product that, through independent studies it was demonstrated to eradicate germs on contact and inhibit their growth. Invented and patented by Emory University, Goldshield®™ is a system of products which includes an antimicrobial that is the first, and only, water-stabilized, non-toxic, non-leaching, environmentally benign solution providing a durable shield against microbial contamination, including mold, mildew and fungi.

Goldshield®™ offers an EPA-registered solution to combat dangerous microbial contamination in virtually every setting including hospitals, outpatient clinics, physicians offices, assisted living facilities, skilled nursing facilities, schools, colleges, athletic clubs, gymnasiums, spas, police departments, emergency medical services, fire departments, correctional institutions, the hospitality industry and commercial laundry facilities, to name a few.

Independent studies conducted at hospitals and universities have demonstrated that Goldshield® is a broad-spectrum bactericide, algaecide and fungicide. In these studies, it has been proven effective against Staphylococcus aureus (Staph), Methicillin-resistant Staphylococcus aureus (MRSA); including HA-MRSA (Healthcare-associated MRSA) and CA-MRSA (community- associated MRSA), Salmonella, E.coli, VRE (Vancomycin-Resistant Enterococci, and other hardy Gram (+) and Gram (-) bacteria. In a recent study in accordance with ASTM (American Society for Testing and Materials) protocols for virucidal efficacy on inanimate surfaces, Goldshield®™ was proven effective against Influenza A as a surrogate for H1N1.

Sharon Harper, an OR nurse and retired, Navy Infection Control Officer, stated, “I have seen the results and can appreciate why Goldshield®™ is so unique. In my opinion, the most exciting use of this new antimicrobial is via a “Bio-Vapor” Steam Cleaning System. This method allows Goldshield®™ to adhere in every ‘nook and cranny’! My mission as the nurse liaison for 24x7 Infection Control, Inc. is to inform government agencies, schools, hospitals, assisted living and long-term care communities that Goldshield®™ is now available.”

The parent company, AP Goldshield LLC is located in the United States, Israel, Asia, and Europe. 24x7 Infection Control, Inc. is an Authorized Distributor for Goldshield®™.

To find out more, please visit www.24x7infectioncontrol.com

Contact:                           
Sharon Harper RN, MSN                                         
LCDR/USN/RET
Sharon (at) 24x7infectioncontrol (dot) com
843-696-6830

###

Read the full story at http://www.prweb.com/releases/NEW/ANTIMICROBIAL/prweb3688064.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
2. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
3. Computers help chemists fight emerging infections
4. Infection contributes to the high rates of oropharyngeal cancers
5. Jefferson immunology researchers halt lethal rabies infection in brain
6. SIV infection of natural hosts provides new insights into HIV disease complexity
7. Novel virus detection identifies new viruses in study of respiratory infections and asthma attacks
8. Natural aorta grafts have few side effects for infection-prone patients
9. Common misdiagnosis: most women believe they have a yeast infection when they dont
10. Patient Safety Authority Board of Directors Names Infection Advisory Panel
11. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
24x7 Infection Control, Inc. Announces World's First, Modern “Shield” Against Microbial Contamination 
(Date:4/24/2017)... Boca Raton, Florida (PRWEB) , ... April 24, 2017 , ... ... natural chai teas, announced its products are now available for purchase on RevNutrition.com, a ... ancient form of tea first produced and popularized in ancient India and Siam. It ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... healthcare compliance and credentialing solutions, today announced that Kyle Allain has joined the ... Cactus Provider Management sales and operations, including provider, payor and managed care solutions. ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... to be diagnosed globally; approximately 25,000 of them will be malignant.(1) As research ... of this type of healthcare model in the diagnosis and treatment of brain ...
(Date:4/24/2017)... IL (PRWEB) , ... April 24, 2017 , ... Rod ... the Senior Housing News website. , Rod has been at the forefront of Gardant ... company’s culture. As CEO, Rod has overseen the opening of more than 40 new ...
(Date:4/24/2017)... ... April 24, 2017 , ... As a former supermodel known for ... The good news for single women is that she put all the words in ... April 25th. Joan's insight, personal experiences and sparkling sense of humor have inspired her ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
Breaking Medicine Technology: